Mapmygenome Acquires dnaPower to Expand North American Labs
The deal centralizes diagnostic testing capabilities across Canada and the US to scale precision health services.
Updated on Oct. 21, 2026 in Biotech
Live Poll
Do you trust that larger health-testing companies provide better, more affordable services to patients?
Mapmygenome has completed its acquisition of Vancouver-based dnaPower Inc. to expand its diagnostic footprint in North America. The deal follows the company's 2025 purchase of Microbiome Insights and aims to unify genetic and microbiome testing services across the US and Canada.
Why it matters
This move consolidates regional laboratory infrastructure to scale capacity for longevity and precision health testing. It signals a shift toward centralized testing platforms that leverage existing local processing hubs for broader international reach.
The integration combines dnaPower's consumer network with Mapmygenome's R&D pipeline and CAP-accredited, ISO-certified laboratory facilities. The Vancouver-based processing hub will now serve as a centralized node for standardized diagnostic workflows.
The players
Mapmygenome
A molecular diagnostics firm operating CAP-accredited clinical labs focused on genetic and microbiome testing.
dnaPower Inc.
A Vancouver-based firm founded in 2008 that provides consumer-facing genetic testing services.
Microbiome Insights
A specialized laboratory provider acquired by Mapmygenome in 2025.
The details
Mapmygenome utilizes CAP-accredited clinical laboratories to ensure high-accuracy genetic sequencing and data analysis. The acquisition of dnaPower, a firm founded in 2008, allows the combined entity to apply these standardized quality control protocols to the North American market. By merging consumer-facing testing services with established R&D pipelines, the company aims to streamline the delivery of results for microbiome and longevity-focused health assessments.
Timeline
2008: dnaPower was founded.
2025: Mapmygenome acquired Microbiome Insights.
October 21, 2026: Mapmygenome completed the acquisition of dnaPower Inc.
The Tech Race
This acquisition follows the precedent of the 2025 Microbiome Insights deal, extending Mapmygenome's consolidation strategy to include dnaPower's consumer market share. It marks a push to secure a dominant position in the North American precision health testing sector.
Consumers in Canada and the US may soon see integrated health reporting that combines genetic data with microbiome analysis. Service availability and specific product transitions for existing dnaPower customers are pending further operational updates.
The takeaway
The acquisition highlights a growing trend of laboratory consolidation to gain economies of scale in the precision health market. Watch for upcoming announcements regarding the integration of consumer data pipelines into Mapmygenome's existing R&D platforms.
Further reading
For broader trends in genetic diagnostics and lab integration, explore our Biotech section.
Live Poll
Do you trust that larger health-testing companies provide better, more affordable services to patients?
